GGrantIndex
Sort

39,280 grants matching leukemia

Proteomic Study of Megakaryocyte Transcriptional Control

$353,930
Alan B. Cantor · Boston Children'S Hospital · R01 · FY2007 · HL

Targeting cell trafficking as a new therapeutic modality for Multiple Myeloma

$353,927
Irene M. Ghobrial · Dana-Farber Cancer Inst · R01 · FY2009 · CA

CLL clonal evolution and the development of therapy-driven resistance

$353,902
Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · P01 · FY2019 · CA

Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia

$353,876
Sinisa Dovat · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2021 · CA

Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia

$353,876
Sinisa Dovat · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2018 · CA

Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia

$353,876
Sinisa Dovat · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2020 · CA

Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia

$353,876
Sinisa Dovat · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2017 · CA

Molecular understanding of cytokine-Ras signals in leukemic bone marrow

$353,777
Jeroen Roose · University Of California, San Francisco · R01 · FY2015 · CA

Molecular understanding of cytokine-Ras signals in leukemic bone marrow

$353,777
Jeroen Roose · University Of California, San Francisco · R01 · FY2017 · CA

Molecular understanding of cytokine-Ras signals in leukemic bone marrow

$353,777
Jeroen Roose · University Of California, San Francisco · R01 · FY2018 · CA

Molecular understanding of cytokine-Ras signals in leukemic bone marrow

$353,777
Jeroen Roose · University Of California, San Francisco · R01 · FY2016 · CA

EASTERN COOPERATIVE ONCOLOGY GROUP

$353,748
Tufts Medical Center · U10 · FY2000 · CA

Studies on ZAP, a broad-spectrum alphavirus inhibitor

$353,697
Margaret R Macdonald · Rockefeller University · R01 · FY2008 · AI

Studies on ZAP, a broad-spectrum alphavirus inhibitor

$353,697
Margaret R Macdonald · Rockefeller University · R01 · FY2009 · AI

Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206

$353,636
Hyung L Kim · Cedars-Sinai Medical Center · R01 · FY2013 · CA

Elucidation of Human Natural Killer Cell Development

$353,610
Aharon G Freud · Ohio State University · R01 · FY2017 · CA

Cytokine Regulation of Photoreceptor Gene Expression

$353,540
John D. Ash · University Of Florida · R01 · FY2015 · EY

HIV-1 AND HIV-2 INFECTION OF NON-DIVIDING CELLS

$353,531
University Of Pennsylvania · R01 · FY2002 · AI

The roles of pleckstrin-2 as a functional node in erythropoiesis

$353,530
Peng Ji · Northwestern University At Chicago · R01 · FY2017 · DK

Clinical Trial Office

$353,508
John C Byrd · Ohio State University · P30 · FY2009 · CA

Combination fusion toxin and cytarabine therapy of AML

$353,500
Wake Forest University Health Sciences · R21 · FY2002 · CA

Discovery of Death Ligands Against Cancers

$353,500
Kit S Lam · University Of California At Davis · R33 · FY2012 · CA

Epigenetic Targeting of Afro-Caribbean Variant of HTLV-1 Related Adult T-cell Leukemia-lymphoma

$353,492
Juan Carlos Ramos · University Of Miami School Of Medicine · R01 · FY2020 · CA

Synthetic rescue of antigen-driven T cells and alloimmunity

$353,491
Yi Zhang · Temple Univ Of The Commonwealth · R56 · FY2019 · AI

c-Abl and PKC-eta in Cell Development and Leukemia

$353,462
Mark S. Schlissel · University Of California Berkeley · R01 · FY2008 · AI